{"id":"meprylcaine","rwe":[{"pmid":"39156775","year":"2024","title":"Key genes and regulatory networks for diabetic retinopathy based on hypoxia-related genes: a bioinformatics analysis.","finding":"","journal":"International journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"37340445","year":"2023","title":"Comprehensive analysis of candidate signatures of long non-coding RNA LINC01116 and related protein-coding genes in patients with hepatocellular carcinoma.","finding":"","journal":"BMC gastroenterology","studyType":"Clinical Study"},{"pmid":"16125150","year":"2005","title":"Inhibition of serotonin transporters by cocaine and meprylcaine through 5-TH2C receptor stimulation facilitates their seizure activities.","finding":"","journal":"Brain research","studyType":"Clinical Study"},{"pmid":"12573515","year":"2003","title":"Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics.","finding":"","journal":"Brain research","studyType":"Clinical Study"},{"pmid":"14296030","year":"1965","title":"THE INTRAVENOUS TOXICITY OF LOCAL ANESTHETIC AGENTS IN MAN.","finding":"","journal":"Clinical pharmacology and therapeutics","studyType":"Clinical Study"}],"tags":[{"label":"meprylcaine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium channel alpha subunits; brain (Types I, II, III)","category":"target"},{"label":"SCN1A","category":"gene"},{"label":"SCN2A","category":"gene"},{"label":"SCN3A","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"oracaine","offLabel":[],"synonyms":["meprylcaine","epirocaine","oracaine","meprylcaine hydrochloride","meprylcaine HCl"],"timeline":[],"approvals":[],"brandName":"Oracaine","ecosystem":[],"mechanism":{"target":"Sodium channel alpha subunits; brain (Types I, II, III)","targets":[{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small Molecule","drugClass":"meprylcaine","explanation":"Imagine your nerves are like electrical wires that carry messages to and from your brain. Sodium channels are like the switches that turn these wires on and off. Oracaine blocks these switches, which can help reduce pain and other symptoms by preventing the transmission of painful signals to the brain.","oneSentence":"Oracaine works by blocking sodium channels in the brain to prevent the transmission of nerve impulses.","technicalDetail":"Oracaine targets the sodium channel alpha subunits (Types I, II, III) in the brain, which are responsible for the initial depolarization phase of the action potential. By blocking these channels, Oracaine reduces the frequency and amplitude of action potentials, leading to a decrease in neuronal excitability and transmission of pain signals."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3770","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEPRYLCAINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:35:02.472218","biosimilars":[],"competitors":[{"drugName":"articaine","drugSlug":"articaine","fdaApproval":"2000-04-03","patentExpiry":"Mar 27, 2039","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bepridil","drugSlug":"bepridil","fdaApproval":"1990-12-28","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"brompheniramine","drugSlug":"brompheniramine","fdaApproval":"1957-08-23","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"butacaine","drugSlug":"butacaine","fdaApproval":"","relationship":"same-target"},{"drugName":"chlorphenamine","drugSlug":"chlorphenamine","fdaApproval":"1950-08-15","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"cinchocaine","drugSlug":"cinchocaine","fdaApproval":"","relationship":"same-target"},{"drugName":"cyproheptadine","drugSlug":"cyproheptadine","fdaApproval":"1961-10-17","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"desipramine","drugSlug":"desipramine","fdaApproval":"1964-11-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"dicycloverine","drugSlug":"dicycloverine","fdaApproval":"1950-05-11","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"meprylcaine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"articaine","brandName":"articaine","genericName":"articaine","approvalYear":"2000","relationship":"same-target"},{"drugId":"bepridil","brandName":"bepridil","genericName":"bepridil","approvalYear":"1990","relationship":"same-target"},{"drugId":"brompheniramine","brandName":"brompheniramine","genericName":"brompheniramine","approvalYear":"1957","relationship":"same-target"},{"drugId":"butacaine","brandName":"butacaine","genericName":"butacaine","approvalYear":"","relationship":"same-target"},{"drugId":"chlorphenamine","brandName":"chlorphenamine","genericName":"chlorphenamine","approvalYear":"1950","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"},{"drugId":"cinchocaine","brandName":"cinchocaine","genericName":"cinchocaine","approvalYear":"","relationship":"same-target"},{"drugId":"cyproheptadine","brandName":"cyproheptadine","genericName":"cyproheptadine","approvalYear":"1961","relationship":"same-target"},{"drugId":"desipramine","brandName":"desipramine","genericName":"desipramine","approvalYear":"1964","relationship":"same-target"},{"drugId":"dicycloverine","brandName":"dicycloverine","genericName":"dicycloverine","approvalYear":"1950","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"82YT7WU9PW","CHEBI":"CHEBI:93147","INN_ID":"370","UMLSCUI":"C0301288","ChEMBL_ID":"CHEMBL127810","KEGG_DRUG":"D01417","PUBCHEM_CID":"4065","SNOMEDCT_US":"15009009","SECONDARY_CAS_RN":"956-03-6"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2024","pmid":"39156775","title":"Key genes and regulatory networks for diabetic retinopathy based on hypoxia-related genes: a bioinformatics analysis.","journal":"International journal of ophthalmology"},{"date":"2023 Jun 20","pmid":"37340445","title":"Comprehensive analysis of candidate signatures of long non-coding RNA LINC01116 and related protein-coding genes in patients with hepatocellular carcinoma.","journal":"BMC gastroenterology"},{"date":"2005 Sep 28","pmid":"16125150","title":"Inhibition of serotonin transporters by cocaine and meprylcaine through 5-TH2C receptor stimulation facilitates their seizure activities.","journal":"Brain research"},{"date":"2003 Feb 21","pmid":"12573515","title":"Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics.","journal":"Brain research"},{"date":"1965 May-Jun","pmid":"14296030","title":"THE INTRAVENOUS TOXICITY OF LOCAL ANESTHETIC AGENTS IN MAN.","journal":"Clinical pharmacology and therapeutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oracaine, also known as meprylcaine, is a small molecule drug that targets sodium channel alpha subunits in the brain. It is classified as a meprylcaine and works by blocking the sodium channels, which are responsible for transmitting nerve impulses. However, due to the lack of available information, its approved indications, half-life, bioavailability, generic manufacturers, and commercial status are unknown. As a result, its clinical use and safety profile cannot be fully assessed. Further research is needed to determine its potential as a therapeutic agent.","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}